TrustFinance is trustworthy and accurate information you can rely on. If you are looking for financial business information, this is the place for you. All-in-One source for financial business information. Our priority is our reliability.

TrustFinance Global Insights
Thg 05 05, 2026
2 min read
29

Former President Donald Trump has reportedly criticized Food and Drug Administration Commissioner Marty Makary for the slow approval process of flavored vapes and nicotine products. According to a Wall Street Journal report, Trump considers the issue significant for his 'Make America Great Again' voter base and has discussed the matter with advisers.
To date, U.S. regulators have not authorized any flavored vape products for sale. The FDA maintains strict evidence requirements, demanding that manufacturers demonstrate a clear benefit to adult smokers that outweighs the risks to youth. Currently, only 41 vape products are legally sold, all of which are tobacco or menthol flavored, reflecting the agency's cautious stance.
A shift in FDA policy could significantly impact the multi-billion dollar vaping industry, potentially opening the market for numerous companies specializing in flavored products. The criticism is linked to a promise Trump made during his campaign to 'save' vaping. Discussions between Trump and Makary have occurred, but no final decision on changing the FDA's position has been confirmed.
The future of flavored vape products remains uncertain, pending further discussions between political figures and regulatory bodies. The outcome could have substantial implications for both the vaping market and public health policy. Investors and consumers are closely monitoring for any official changes from the FDA.
Q: Why is Donald Trump involved in the flavored vape issue?
A: Trump reportedly believes the availability of flavored vapes is a key issue for his voters and has previously pledged to support the industry.
Q: What is the FDA's current stance on flavored vapes?
A: The FDA has not approved any flavored vape products, citing the need for strict evidence that their benefits to adult smokers outweigh the appeal and risk to youth.
Source: Investing.com

TrustFinance Global Insights
AI-assisted editorial team by TrustFinance curating reliable financial and economic news from verified global sources.
Related Articles

18 Thg 05 2026
Goldman Sachs Warns Energy Shock Could Boost US Dollar

18 Thg 05 2026
Asian Stocks Slip Amid Tech Losses, Mideast Tensions

18 Thg 05 2026
Hancock Prospecting Adds Defence Stocks to US Portfolio

18 Thg 05 2026
Trump Proposes White House Helipad for South Lawn

18 Thg 05 2026
Asian FX Weakens on Iran Tensions, Soft China Data

18 Thg 05 2026
Samsung Stock Jumps as SKorea Averts Chip Strike